MolMed S.p.A. and TTY Biopharm Company Ltd. (TTY) recently announced they signed an exclusive license and distribution agreement to import, use, market, sell and/or distribute Zalmoxis in Taiwan, Hong Kong, Vietnam, Philippines, Thailand, Malaysia, and Singapore. Zalmoxis has been approved by the European Commission (EMA) for the treatment of adult patients affected by leukaemia or for other high-risk haematological malignancies, in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT);this's also the first patient-specific cell therapy.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
78.3 TWD | -3.93% | -4.28% | -2.61% |
Mar. 14 | TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 08 | TTY Biopharm Company Limited Announces Change of CFO and Financial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.61% | 608M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock TTY Biopharm Company Limited - Taipei Exchange
- News TTY Biopharm Company Limited
- MolMed S.p.A. and TTY Biopharm Company Ltd Announce Exclusive License and Distribution Agreement